495 related articles for article (PubMed ID: 25472998)
1. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy.
Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L
Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998
[TBL] [Abstract][Full Text] [Related]
2. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function.
Hernandez-Chacon JA; Li Y; Wu RC; Bernatchez C; Wang Y; Weber JS; Hwu P; Radvanyi LG
J Immunother; 2011 Apr; 34(3):236-50. PubMed ID: 21389874
[TBL] [Abstract][Full Text] [Related]
3. Co-stimulation through 4-1BB/CD137 improves the expansion and function of CD8(+) melanoma tumor-infiltrating lymphocytes for adoptive T-cell therapy.
Chacon JA; Wu RC; Sukhumalchandra P; Molldrem JJ; Sarnaik A; Pilon-Thomas S; Weber J; Hwu P; Radvanyi L
PLoS One; 2013; 8(4):e60031. PubMed ID: 23560068
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB Agonist Focuses CD8
Sakellariou-Thompson D; Forget MA; Creasy C; Bernard V; Zhao L; Kim YU; Hurd MW; Uraoka N; Parra ER; Kang Y; Bristow CA; Rodriguez-Canales J; Fleming JB; Varadhachary G; Javle M; Overman MJ; Alvarez HA; Heffernan TP; Zhang J; Hwu P; Maitra A; Haymaker C; Bernatchez C
Clin Cancer Res; 2017 Dec; 23(23):7263-7275. PubMed ID: 28947567
[No Abstract] [Full Text] [Related]
5. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
6. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD137 monoclonal antibodies and adoptive T cell therapy: a perfect marriage?
Weigelin B; Bolaños E; Rodriguez-Ruiz ME; Martinez-Forero I; Friedl P; Melero I
Cancer Immunol Immunother; 2016 May; 65(5):493-7. PubMed ID: 26970765
[TBL] [Abstract][Full Text] [Related]
8. Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors.
Hall M; Liu H; Malafa M; Centeno B; Hodul PJ; Pimiento J; Pilon-Thomas S; Sarnaik AA
J Immunother Cancer; 2016; 4():61. PubMed ID: 27777771
[TBL] [Abstract][Full Text] [Related]
9. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
[TBL] [Abstract][Full Text] [Related]
10. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
11. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes.
Ju SA; Lee SC; Kwon TH; Heo SK; Park SM; Paek HN; Suh JH; Cho HR; Kwon B; Kwon BS; Kim BS
Immunol Cell Biol; 2005 Aug; 83(4):344-51. PubMed ID: 16033529
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
[TBL] [Abstract][Full Text] [Related]
13. Restoration of tumor-specific HLA class I restricted cytotoxicity in tumor infiltrating lymphocytes of advanced breast cancer patients by in vitro stimulation with tumor antigen-pulsed autologous dendritic cells.
Kass R; Bellone S; Palmieri M; Canè S; Bignotti E; Henry-Tillman R; Hutchins L; Cannon MJ; Klimberg S; Santin AD
Breast Cancer Res Treat; 2003 Aug; 80(3):275-85. PubMed ID: 14503800
[TBL] [Abstract][Full Text] [Related]
14. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.
Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R
Cancer Immunol Immunother; 2014 Oct; 63(10):1061-71. PubMed ID: 24993563
[TBL] [Abstract][Full Text] [Related]
16. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
Schiltz PM; Beutel LD; Nayak SK; Dillman RO
J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
[TBL] [Abstract][Full Text] [Related]
17. 4-1BB-Enhanced Expansion of CD8
Harao M; Forget MA; Roszik J; Gao H; Babiera GV; Krishnamurthy S; Chacon JA; Li S; Mittendorf EA; DeSnyder SM; Rockwood KF; Bernatchez C; Ueno NT; Radvanyi LG; Vence L; Haymaker C; Reuben JM
Cancer Immunol Res; 2017 Jun; 5(6):439-445. PubMed ID: 28473315
[TBL] [Abstract][Full Text] [Related]
18. Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma.
Tavera RJ; Forget MA; Kim YU; Sakellariou-Thompson D; Creasy CA; Bhatta A; Fulbright OJ; Ramachandran R; Thorsen ST; Flores E; Wahl A; Gonzalez AM; Toth C; Wardell S; Mansaray R; Radvanyi LG; Gombos DS; Patel SP; Hwu P; Amaria RN; Bernatchez C; Haymaker C
J Immunother; 2018; 41(9):399-405. PubMed ID: 29757889
[TBL] [Abstract][Full Text] [Related]
19. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.
Dudley ME; Wunderlich JR; Shelton TE; Even J; Rosenberg SA
J Immunother; 2003; 26(4):332-42. PubMed ID: 12843795
[TBL] [Abstract][Full Text] [Related]
20. In vitro 4-1BB stimulation promotes expansion of CD8
Nielsen M; Krarup-Hansen A; Hovgaard D; Petersen MM; Loya AC; Westergaard MCW; Svane IM; Junker N
Cancer Immunol Immunother; 2020 Nov; 69(11):2179-2191. PubMed ID: 32472369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]